#1 Clinical Trials Search in Europe

Zipalertinib

Zipalertinib is an investigational drug being studied in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC), particularly in patients with specific EGFR mutations. These trials aim to evaluate the safety and efficacy of Zipalertinib alone or in combination with chemotherapy, compared to standard treatments. The studies focus on patients with EGFR exon 20 insertion mutations and other uncommon EGFR mutations, offering hope for improved outcomes in this challenging subset of lung cancer patients.

Table of Contents

What is Zipalertinib?

Zipalertinib, also known as TAS6417 or CLN-081, is an investigational medication being developed for the treatment of advanced non-small cell lung cancer (NSCLC)[1]. It is specifically designed to target certain genetic mutations in lung cancer cells, offering a potential new treatment option for patients with specific types of NSCLC.

How Does Zipalertinib Work?

Zipalertinib belongs to a class of drugs called EGFR tyrosine kinase inhibitors (TKIs). It works by targeting and blocking the activity of a specific protein called the epidermal growth factor receptor (EGFR) when it has certain mutations[1]. By inhibiting this protein, zipalertinib can potentially slow down or stop the growth of cancer cells that depend on these mutated EGFR proteins to survive and multiply.

Who Can Benefit from Zipalertinib?

Zipalertinib is being studied for patients with advanced or metastatic NSCLC who have specific EGFR mutations, particularly:

  • EGFR exon 20 insertion mutations: These are less common mutations that are often resistant to existing EGFR-targeted therapies[1].
  • Uncommon single or compound EGFR mutations: These are rarer mutations that may not respond well to current treatments[2].

Patients with brain metastases (cancer that has spread to the brain) from NSCLC may also be eligible for treatment with zipalertinib in certain clinical trials[2].

Clinical Trials and Research

Zipalertinib is currently being evaluated in several clinical trials to assess its safety and effectiveness. Two notable studies include:

  1. A Phase 3 trial comparing zipalertinib plus chemotherapy to chemotherapy alone in patients with previously untreated, advanced NSCLC with EGFR exon 20 insertion mutations[1]. This study aims to determine if adding zipalertinib to standard chemotherapy can improve outcomes for patients.

  2. A Phase 2b trial evaluating zipalertinib in patients with advanced NSCLC who have EGFR exon 20 insertion mutations or other uncommon EGFR mutations[2]. This study includes patients who may have received prior treatments and those with brain metastases.

These trials are designed to measure how well zipalertinib works by looking at factors such as:

  • Objective response rate (ORR): The percentage of patients whose tumors shrink or disappear with treatment[2].
  • Progression-free survival (PFS): How long patients live without their cancer getting worse[1].
  • Overall survival (OS): How long patients live overall[2].
  • Intracranial efficacy: How well the drug works against brain metastases[2].

Potential Side Effects

As with all medications, zipalertinib may cause side effects. While the full safety profile is still being studied, some potential side effects based on similar drugs in its class may include:

  • Skin rash or dryness
  • Diarrhea
  • Fatigue
  • Decreased appetite
  • Nausea

It’s important to note that the clinical trials are closely monitoring for any adverse events to ensure patient safety[1][2]. Patients participating in these trials will be carefully watched for any side effects and will receive appropriate medical care.

Administration and Dosage

Zipalertinib is taken orally in the form of tablets[1][2]. The exact dosage and schedule are still being determined through clinical trials. In the studies mentioned, the maximum daily dose being tested is 100 mg[2]. However, it’s important to remember that the optimal dose may change based on the results of these trials.

Patients should always follow their doctor’s instructions regarding medication use and report any side effects or concerns promptly.

Aspect Details
Drug Name Zipalertinib (TAS6417/CLN-081)
Target Condition Advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations or other uncommon EGFR mutations
Trial Phases Phase 2b and Phase 3
Treatment Approaches 1. Zipalertinib monotherapy 2. Zipalertinib in combination with chemotherapy (pemetrexed and platinum agent)
Key Endpoints 1. Objective Response Rate (ORR) 2. Progression-Free Survival (PFS) 3. Overall Survival (OS) 4. Safety and tolerability 5. Intracranial efficacy for patients with brain metastases
Patient Populations 1. Previously treated patients 2. Treatment-naive patients 3. Patients with brain metastases
Administration Oral tablet, daily dosing
Unique Features 1. Focus on EGFR exon 20 insertion mutations 2. Inclusion of patients with brain metastases 3. Evaluation of intracranial efficacy

FAQ

  • What is Zipalertinib? Zipalertinib is an investigational drug being studied for the treatment of advanced non-small cell lung cancer (NSCLC), particularly in patients with specific EGFR mutations such as exon 20 insertion mutations.
  • What types of patients are being studied in these clinical trials? The trials are focusing on patients with locally advanced or metastatic NSCLC who have EGFR exon 20 insertion mutations or other uncommon EGFR mutations. Some trials include previously treated patients, while others are studying Zipalertinib as a first-line treatment.
  • How is Zipalertinib being administered in these trials? Zipalertinib is being administered orally in tablet form. In some trials, it is being studied in combination with standard chemotherapy drugs like pemetrexed and a platinum agent (either carboplatin or cisplatin).
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the safety and efficacy of Zipalertinib. They aim to determine the optimal dose, evaluate response rates, measure progression-free survival, and assess overall survival in patients treated with Zipalertinib alone or in combination with chemotherapy.
  • Are patients with brain metastases included in these trials? Yes, some of the trials include patients with brain metastases, provided they meet specific criteria. One trial even has a dedicated cohort for patients with brain metastases or leptomeningeal disease to evaluate the intracranial efficacy of Zipalertinib.

Ongoing Clinical Trials on Zipalertinib

  • Study on the Safety and Effectiveness of Zipalertinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Specific EGFR Mutations

    Recruiting

    2 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy The Netherlands +3

  • Study of Zipalertinib with Chemotherapy vs. Chemotherapy Alone for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Greece Italy +4

Glossary

  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the most common form, accounting for about 80-85% of all lung cancers. It grows and spreads more slowly than small cell lung cancer.
  • EGFR (Epidermal Growth Factor Receptor): A protein found on the surface of some cells that helps them grow and divide. Mutations in the EGFR gene can lead to excessive cell growth and cancer.
  • Exon 20 Insertion Mutation: A specific type of mutation in the EGFR gene that occurs in a region called exon 20. This mutation is associated with resistance to some common EGFR-targeted therapies.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, version 1.1. A standard way to measure how well a cancer patient responds to treatment.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Leptomeningeal Disease: A condition where cancer cells spread to the membranes (meninges) surrounding the brain and spinal cord.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a dose reduction.

References

  1. http://clinicaltrials.eu/trial/study-of-zipalertinib-with-chemotherapy-vs-chemotherapy-alone-for-patients-with-advanced-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-zipalertinib-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-with-specific-egfr-mutations/